Terns Pharmaceuticals Welcomes Robert Azelby to Board of Directors

Terns Pharmaceuticals has announced the appointment of seasoned biotech executive Robert Azelby to its Board of Directors, bringing decades of experience in drug development and commercialization. Azelby’s extensive background includes leadership roles at Eliem Therapeutics, Alder BioPharmaceuticals, Juno Therapeutics, and Amgen, making him a valuable asset as Terns advances its clinical programs. His expertise will be particularly impactful as the company pushes forward with late-stage studies for TERN-701, its lead candidate in chronic myeloid leukemia.

In this transition, Carl Gordon will be stepping down from the board after more than seven years of service. CEO Amy Burroughs expressed gratitude for Gordon’s contributions, noting his role in shaping the company’s strategic direction from its early days. She also welcomed Azelby, highlighting his strong track record in commercializing breakthrough treatments. Azelby himself shared his excitement about joining Terns, emphasizing his commitment to supporting the company’s mission of delivering innovative therapies to patients with serious conditions.